Valeant Pharmaceuticals International’s (VRX) Hold Rating Reiterated at HC Wainwright

HC Wainwright restated their hold rating on shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) in a research note released on Monday morning. They currently have a $17.00 price objective on the specialty pharmaceutical company’s stock.

A number of other analysts have also commented on the stock. Royal Bank Of Canada set a $19.00 price objective on shares of Valeant Pharmaceuticals International and gave the company a sector perform rating in a research note on Monday, June 19th. Zacks Investment Research lowered shares of Valeant Pharmaceuticals International from a hold rating to a strong sell rating in a research note on Thursday, July 13th. ValuEngine lowered shares of Valeant Pharmaceuticals International from a buy rating to a hold rating in a research note on Friday, September 1st. Wells Fargo & Company dropped coverage on shares of Valeant Pharmaceuticals International in a research note on Sunday, July 30th. Finally, Vetr lowered shares of Valeant Pharmaceuticals International from a strong-buy rating to a sell rating and set a $13.30 price objective for the company. in a research note on Thursday, August 24th. Five investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of Hold and a consensus target price of $17.62.

Shares of Valeant Pharmaceuticals International (NYSE:VRX) opened at 14.23 on Monday. The stock’s market capitalization is $4.96 billion. Valeant Pharmaceuticals International has a one year low of $8.31 and a one year high of $27.84. The stock’s 50 day moving average is $14.22 and its 200-day moving average is $13.18.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last posted its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 EPS for the quarter, beating analysts’ consensus estimates of $0.97 by $0.08. Valeant Pharmaceuticals International had a negative net margin of 12.40% and a positive return on equity of 59.89%. The company had revenue of $2.23 billion during the quarter, compared to analyst estimates of $2.23 billion. During the same period in the prior year, the firm earned ($0.88) earnings per share. The business’s quarterly revenue was down 7.7% on a year-over-year basis. On average, equities research analysts expect that Valeant Pharmaceuticals International will post $3.89 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Valeant Pharmaceuticals International’s (VRX) Hold Rating Reiterated at HC Wainwright” was published by BBNS and is the property of of BBNS. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://baseballnewssource.com/markets/valeant-pharmaceuticals-internationals-vrx-hold-rating-reiterated-at-hc-wainwright/1656748.html.

In other news, Director Schutter Richard U. De bought 10,000 shares of Valeant Pharmaceuticals International stock in a transaction that occurred on Monday, August 21st. The stock was purchased at an average cost of $14.33 per share, with a total value of $143,300.00. Following the completion of the transaction, the director now directly owns 77,479 shares in the company, valued at $1,110,274.07. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.87% of the stock is owned by company insiders.

A number of hedge funds have recently modified their holdings of VRX. Armstrong Henry H Associates Inc. raised its stake in Valeant Pharmaceuticals International by 0.3% during the second quarter. Armstrong Henry H Associates Inc. now owns 93,753 shares of the specialty pharmaceutical company’s stock worth $1,622,000 after acquiring an additional 295 shares in the last quarter. World Asset Management Inc raised its stake in Valeant Pharmaceuticals International by 1.5% during the first quarter. World Asset Management Inc now owns 21,502 shares of the specialty pharmaceutical company’s stock worth $237,000 after acquiring an additional 328 shares in the last quarter. Eaton Vance Management raised its stake in Valeant Pharmaceuticals International by 1.2% during the second quarter. Eaton Vance Management now owns 43,469 shares of the specialty pharmaceutical company’s stock worth $752,000 after acquiring an additional 500 shares in the last quarter. IFP Advisors Inc raised its stake in Valeant Pharmaceuticals International by 0.4% during the second quarter. IFP Advisors Inc now owns 128,305 shares of the specialty pharmaceutical company’s stock worth $2,220,000 after acquiring an additional 509 shares in the last quarter. Finally, NEXT Financial Group Inc raised its stake in Valeant Pharmaceuticals International by 6.2% during the second quarter. NEXT Financial Group Inc now owns 10,303 shares of the specialty pharmaceutical company’s stock worth $178,000 after acquiring an additional 600 shares in the last quarter. 50.47% of the stock is owned by hedge funds and other institutional investors.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with our FREE daily email newsletter.

 


Latest News

American League Once Again Dominates National League
American League Once Again Dominates National League
Los Angeles Dodgers Waiting But Magic Number Down to One
Los Angeles Dodgers Waiting But Magic Number Down to One
Young Girl Hit by Foul Ball Rushed to Hospital
Young Girl Hit by Foul Ball Rushed to Hospital
New Home Run Record Reached in Major League Baseball
New Home Run Record Reached in Major League Baseball
Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22


Leave a Reply

 
© 2006-2017 BBNS.